CLINICAL_TRIALS
trial_result
· 2015-06-18
Clinical Trial Update: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia [Phase 3]
Summary
Phase 3 study of paliperidone palmitate 3-month formulation for schizophrenia has completed. Results were posted on June 18, 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2015-06-18